{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:21:32Z","timestamp":1790223692837,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet\u2010derived growth factor receptor \u03b2 (PDGFR\u2010\u03b2), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2\u2010B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum\u2010containing chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Fleming single\u2010arm, single\u2010stage, phase 2 trial to evaluate the activity of regorafenib (160\u00a0mg once a day by mouth for 3\u00a0weeks on\/1\u00a0week off) was planned. The study was designed to reject the null hypothesis of an 8\u2010week progression\u2010free survival (PFS) rate \u226425% with a type I error of 0.10 and a statistical power of 80% at the alternative hypothesis of an 8\u2010week PFS rate of \u226550% (\u22658 of 19 evaluable patients progression\u2010free at 2\u00a0months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From June 2016 to November 2017, 19 patients were enrolled (11T\/8TC). We observed partial response (PR) in 1 patient (1T) (5.3%), stable disease (SD) in 14 patients (9T\/5TC) (73.7%), and progressive disease in 2 patients (1T\/1TC) (10.5%), with a disease control rate of 78.9%. According to Choi\u2010criteria, 13 patients (68.4%) achieved PR, and 2 patients SD (10.5%). The median PFS was 9.6\u00a0months whereas median overall survival was 33.8\u00a0months. The 8\u2010week PFS rate was 78.9% (15 of 19 patients). Grade 3\u20104 treatment\u2010related adverse events were observed in 10 patients (52.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The primary end point of this study was reached. The high rate of PR (Choi\u2010criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.33990","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T16:11:42Z","timestamp":1635351102000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2\u2010B3) and thymic carcinoma previously treated with chemotherapy"],"prefix":"10.1002","volume":"128","author":[{"given":"Matteo","family":"Perrino","sequence":"first","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS European Institute of Oncology Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Biostatistic Unit IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"De Vincenzo","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-0502","authenticated-orcid":false,"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS European Institute of Oncology Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Digiacomo","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cordua","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D'Antonio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Borea","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-1702","authenticated-orcid":false,"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS Humanitas Research Hospital Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1f62d"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.11.015"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097\u20100142(19811201)48:11<2485:aid\u2010cncr2820481123>3.0.co;2\u2010r"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0487"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1164"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010014\u20101800\u20106"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.094"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2737"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp483"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.06.020"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019\u20100593"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25367"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.92"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201012\u20103260"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3016"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200406173502523"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8963"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn388"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(07)70141\u20109"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.009"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7068"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181b6be57"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4467"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(13)70596\u20105"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8519"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)71181\u20107"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.04.024"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30162\u20105"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4078"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30062\u20107"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2002.124389"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005950170021"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2007.05.003"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.13765"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102613.2011.00777.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.011"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3049"},{"key":"e_1_2_8_42_1","unstructured":"National Cancer Institute. Common Toxicity Criteria Manual version 4.0. Accessed May 28 2009.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009\u201005\u201029_QuickReference_8.5x11.pdf"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013\u20100114"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33990","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:49:06Z","timestamp":1760280546000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2,15]]}},"alternative-id":["10.1002\/cncr.33990"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33990","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"2021-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}